CompletedNCT01633008Updated Sep 30, 2019

Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain

An Early Phase 1 interventional study of ACT Workshop in Neurofibromatosis, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 12 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by National Cancer Institute (NCI) · Early Phase 1, Interventional, and Treatment

Phase: Early Phase 1
Study type: Interventional
Enrollment: 28
Allocation: Non-randomized
Ages: 12 Years to 99 Years
Sex: All

Study summary

Background:

Neurofibromatosis type 1 (NF1) is a genetic disorder that can cause frequent and significant pain. This pain can have a severe impact on a person s quality of life.
Acceptance and Commitment Therapy (ACT) is a new type of therapy that may help people manage pain. It teaches behavioral techniques that can be used to change how people react to pain. ACT may help people with NF1 cope better with the pain associated with the disorder. Researchers want to test ACT techniques to see if they can improve coping in people with NF1 pain.

Objectives:

To see if ACT can help treat chronic pain in adolescents and young adults who have NF1.

Eligibility:

Adolescents and young adults between 12 and 21 years of age who have chronic pain associated with NF1.

Design:

Participants will be screened with a physical exam and medical history. They will also complete a set of questionnaires about their pain levels, quality of life, and medications that they are taking.
Participants will take part in a training workshop for ACT. It will consist of three 2-hour sessions over 2 consecutive days. The workshop will teach techniques for setting goals that reflect personal values, and changing the focus from pain avoidance to pain management. There will be practice exercises between each session.
At the end of the workshop, participants will receive a workbook with the exercises to continue to practice at home. Participants will be encouraged to spend at least 20 minutes, three times per week, on these practice exercises.
There will be a followup phone call to check on pain management after the workshop.
Three months after the first study visit, participants will complete the study questionnaires again from home. They will provide more information about how they are managing their pain. The questionnaires will be returned by mail in an envelope provided by the study team.

Read the detailed description

Background:

Neurofibromatosis type 1 (NF1) is a genetic disorder that affects approximately 1 in 3,500 individuals.
A number of common clinical manifestations, including plexiform neurofibromas, scoliosis, and chronic headaches, can cause frequent and significant pain and impact quality of life.
Often, NF1-related pain is not well-controlled with medication and many of the medications cause significant side effects.
To our knowledge, no studies have examined the effectiveness of behavioral interventions for chronic pain in individuals with NF1.
Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain or distress.
- In helping individuals with pain, the goal of ACT is not to eliminate the person s pain, but to optimize the person s quality of life despite their pain.

Objectives:

To evaluate whether the Acceptance and Commitment Therapy (ACT) group demonstrates improvement on the Modified Brief Pain Inventory scale from baseline to 3 months in adolescents and young adults with NF1 and chronic pain.
To examine changes in patient s functional ability, quality of life, pain-related coping, pain-related anxiety, pain severity, and depression from baseline to 3 months
To examine the effects of ACT on parents psychological well-being, overall stress, and ability to cope with their child s pain
To explore the relationship between changes in patients pain interference, functional ability, pain-related coping, pain-related anxiety, pain severity, depression and treatment adherence with demographic variables, parent stress, and parent coping
To collect preliminary data on the value of ACT to guide the potential development of a future phase II trial

Eligibility:

Patients ages 12 to 21 with a confirmed diagnosis of NF1.-Parents of participating patients.-The patient must indicate a score of 3 or higher on a pain item (1 5 scale) from a quality of life measure assessing the extent to which pain has interfered with the patient s daily functioning over the past month.

Design:

This is a behavioral study to determine the feasibility and potential benefit of an ACT intervention on pain interference from baseline to 3 months post-intervention.
A sample size of 12 patients is needed to provide 90% power for detecting a change of .77 standard deviations on the total pain interference score of the M-BPI using a 1-sided .1 level test.
ACT workshops will be scheduled multiple times over approximately five months and will be comprised of three 2-hour sessions held over two consecutive days
Measures assessing pain interference, pain coping, pain-related anxiety, quality of life, functional disability, depression, and pain severity will be administered to patients prior to the ACT intervention and 3 months later.
At the same time points, a parent or legal guardian of each patient will complete measures assessing their child s quality of life, functional disability, depression, and pain severity, as well as the parent s own psychological functioning and ability to cope with their child s pain

Conditions studied

Neurofibromatosis

Browse trials for

Keywords

Modified Brief Pain Inventory
Quality of Life
Pain-Related Coping
Pain-Related Anxiety
Depression

In context

Neurofibromatoses

186 studies on the registry are indexed under Neurofibromatoses; 24 are open to participants now.

This study's enrollment of 28 is close to the median of 26 across 120 interventional studies indexed under Neurofibromatoses.

Browse Neurofibromatoses studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,506 studies on the registry; 334 are open to participants now.

Of its 402 completed or terminated interventional studies of FDA-regulated products, 365 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 12 Years to 99 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Eligibility criteria

INCLUSION CRITERIA FOR PARTICIPANT:

Subjects must be between 12 and 21 years of age at the time of the intervention. Because the research on the effectiveness of ACT with children younger than 12 is still emerging, children 11 and younger will be excluded from the present study.

For the clinical diagnosis of NF1 all study subjects must have two or more diagnostic criteria for NF1 listed below (NIH Consensus Conference):

Six or more cafe-au-lait spots (greater than or equal to 0.5 cm in prepubertal subjects or greater than or equal to 1.5 cm in postpuberta subjects)
Greater than or equal to 2 neurofibromas or 1 plexiform neurofibroma
Freckling in the axilla or groin
Optic glioma
Two or more Lisch nodules
A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or thinning of long bone cortex)
A first-degree relative with NF1
Response of 3 or higher on a pain item (1 5 scale) from a self-report quality of life measure (Impact of Pediatric Illness Scale) assessing the extent to which pain has interfered with the patient s daily functioning over the past month.
Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
Subjects may be participating in other medical interventions for the treatment of their disease, or standard care techniques for pain management.
No anticipated major changes in their pain regimen or enrollment on a new treatment study in the near future.
Subjects must be able to read and comprehend the English language.
EXCLUSION CRITERIA FOR PARTICIPANT:
In the opinion of the PI or an AI, the subject has significant cognitive or emotional difficulties that would prevent them from being able to understand and/or participate fully in the intervention or the measures.
Subjects who are participating in any other treatment studies, either medical or behavioral, for pain management.
Subjects who are scheduled to begin a new drug protocol for the treatment of their NF1 during the time of their enrollment on the current study.
Inability to travel to the NIH, for example, due to physical limitations, for the scheduled workshop and evaluations.
No groups in regards to gender, race, or ethnicity are being excluded from participation in the trial.
INCLUSION CRITERIA FOR PARENTS:
Parents must have a child with NF1 who is participating in this protocol as a patient.
Ability to read and comprehend the English language.
Ability to understand and the willingness to sign a written informed consent document.
If a minor patient meets all eligibility criteria but his or her parent does not (i.e., in the case where a parent does not speak English), the patient will not be allowed to participate.

Study design

Phase: Early Phase 1
Primary purpose: Treatment
Allocation: Non-randomized
Intervention model: Single group
Masking: None (open label)
Enrollment: 28 participants (actual)

Study arms

Experimental
1
Attend three 2-hour sessions held over two consecutive days
Behavioral: ACT Workshop

Interventions

BehavioralACT Workshop
The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques

What researchers measure

Primary outcomes

Pain improvement
Time frame: 3 months

Secondary outcomes

Value of the ACT for future Ph2 trial.
Time frame: 6 months
Psychological well-being & stress changes in parents
Time frame: 3 months
Explore improvements of pain interference, abilities, coping, anxiety,depression, etc
Time frame: 3 months
Relationship between pain and treatment adherence
Time frame: 3 months

Study locations

1 site

National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland 20892, United States

References and documents

Publications

Babovic-Vuksanovic D, Widemann BC, Dombi E, Gillespie A, Wolters PL, Toledo-Tamula MA, O'Neill BP, Fox E, MacDonald T, Beck H, Packer RJ. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol. 2007 May;36(5):293-300. doi: 10.1016/j.pediatrneurol.2007.01.009. PubMed 17509460 ↗
Bach P, Hayes SC. The use of acceptance and commitment therapy to prevent the rehospitalization of psychotic patients: a randomized controlled trial. J Consult Clin Psychol. 2002 Oct;70(5):1129-39. doi: 10.1037//0022-006x.70.5.1129. PubMed 12362963 ↗
Blount RL, Cohen LL, Frank NC, Bachanas PJ, Smith AJ, Manimala MR, Pate JT. The Child-Adult Medical Procedure Interaction Scale-Revised: an assessment of validity. J Pediatr Psychol. 1997 Feb;22(1):73-88. doi: 10.1093/jpepsy/22.1.73. PubMed 9019049 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01633008
Lead sponsor: National Cancer Institute (NCI)
Responsible party: Sponsor
First posted: Jul 4, 2012
Start date: Jun 15, 2012
Primary completion: May 1, 2014
Completion: Jan 10, 2017
Last update: Sep 30, 2019

Study contacts

Staci M Peron, Ph.D.

principal investigator · National Cancer Institute (NCI)

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neurofibromatoses→

Other studies from this sponsor

National Cancer Institute (NCI)

Start the discussion